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Background: Trypanosoma cruzi, the etiological agent of Chagas’ disease, is an obligate intracellular parasite which
induces a CD8+ T cell immune response with secretion of cytokines and release of cytotoxic granules. Although an
immune-suppressive effect of T. cruzi on the acute phase of the disease has been described, little is known about
the capacity of CD8+ T cell from chronic chagasic patients to respond to a non-T. cruzi microbial antigen.
Methods: In the present paper, the frequency, phenotype and the functional activity of the CD8+ T cells specific
from Flu-MP*, an influenza virus epitope, were determined in 13 chagasic patients and 5 healthy donors.
Results: The results show that Flu-MP* peptide specific CD8+ T cells were found with similar frequencies in both
groups. In addition, Flu-MP* specific CD8+ T cells were distributed in the early or intermediate/late differentiation
stages without showing enrichment of a specific sub-population. The mentioned Flu-MP* specific CD8+ T cells from
chagasic patients were predominately TEM (CCR7- CD62L-), producing IL-2, IFNγ, CD107a/b and perforin, and did
not present significant differences when compared with those from healthy donors.
Conclusions: Our results support the hypothesis that there is no CD8+ T cell nonspecific immune-suppression
during chronic Chagas disease infection. Nonetheless, other viral antigens must be studied in order to confirm
our findings.
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Chagas’ disease, caused by the hemoflagellate parasite Try-
panosoma cruzi, has a widespread distribution in Central
and South America. Approximately 10 million people are
infected along 21 endemic countries of Latin-America [1].
However, due to increasing migration to North America
and Europe, the disease has been expanded beyond its ori-
ginal borders [2,3]. Infection with T. cruzi, results in a gen-
erally asymptomatic disease due to the fact that most of
the infected individuals remains in an indeterminate
chronic phase. After the acute phase, the disease becomes
clinically evident in 30-40% of them with cardiac or di-
gestive manifestations (symptomatic chronic phase) [4-7].* Correspondence: cpuerta@javeriana.edu.co
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reproduction in any medium, provided the orTrypanosoma cruzi is an obligate intracellular parasite
which invades and replicates into mammalian cells. As
other intracellular infectious agents, T. cruzi induces a
CD8+ T cell immune response with secretion of cytokines
and release of cytotoxic granules [8,9]. The role of CD8+ T
cells is crucial for controlling the T. cruzi infection. Indeed,
during the acute infection, depleted CD8+ T cells mice
showed increased parasite burden in their hearts, moder-
ate decrease in the inflammation and higher mortality
compared with wild type infected animals [10]. Nonethe-
less, in chronic infection, there are several experimental
data supporting that the suboptimal generation of func-
tional specific effector CD8+ T cells leads to the lack of in-
fection control and parasite persistence in the tissues
[11,12]. Thus, the presence of late-differentiated CD8+ T
cells exhibiting signs of senescence that are incapable of
maintaining effector functions [11-13], and the diversity of
T. cruzi antigens that can enter MHC class I processingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and antigen focused cellular immune response [8,14]. Due
to the parasite’s genetic complexity and a high degree of
polymorphism among strains, only a few human CD8+ T
cell parasite-specific epitopes capable of inducing specific
CD8+ T cell responses have been described [14-21]. Fur-
thermore, even less is known about the capacity of chaga-
sic patients to respond to non-chagasic microbial antigens.
A T. cruzi-induced nonspecific immune-suppression dur-
ing the acute phase of the disease has been reported by sev-
eral authors, showing the immunosuppressive effect on
dendritic cells, macrophages, splenic T cells, and LTs [22-
25]. Nonetheless, experimental infection in mice indicated
that there is no general immunosuppressive effect of T.
cruzi on CD8+ T cell priming [26]. No data of CD8+ T cell
immune-suppression have been reported with another
derived-microbial epitopes in humans infected with T. cruzi.
The aim of the present work was to determine whether
or not there is a nonspecific immune-suppression in
chronic chagasic patients. Consequently, we investigated
the CD8+ T cells response against a representative viral
antigen. Thus, we examined the frequency, phenotype and
the functional activity of the influenza virus specific CD8+
T cells in chagasic patients and healthy donors. We selected
an epitope from the viral matrix protein because the major-
ity of individuals throughout their life have been exposed to
the influenza virus and have had at least one infection.Results
Population HLA-A2 subtyping
In this work we assessed whether the CD8+ T cells from
T. cruzi infected patients are able to respond to non-T.
cruzi microbial antigens such as a well described epitope
from influenza virus derived from the matrix protein. Spe-
cifically, it was studied whether the frequency, phenotype
and functional capacity of Flu-specific CD8+ T cells are
modified in chronic chagasic patients with respect to
healthy donors used as control. The Flu-MP* peptide,Figure 1 Frequency of CD8+ T cells specific for Flu-MP* peptide deter
plot from one HLA-A*0201+ chagasic patient. (B) Frequency of HLA-A*0201
(grey bars). There were no statistically significant differences between healtwhich is an HLA-A*0201 restricted epitope was used as
non-T cruzi epitope since HLA-A*0201 is the most preva-
lent human class I allele [27]. Consequently, subjects were
HLA-A2 typed by flow cytometry and subtyped for HLA-
A*0201 by PCR. It was found that 13 out of 50 chagasic
patients (26%) were HLA-A2+; from whom all were HLA-
A*0201+, classified as six chronic patients in indeterminate
phase or A stage (normal electrocardiography ECG, and
no major findings arising during clinical examination) and
seven symptomatic chagasic patients having different dis-
ease severity levels as follows: 2 B (abnormal ECG results),
3 C (abnormal ECG results, decreased left ventricular
ejection fraction, LVEF, and cardiac enlargement) and 2 D
(abnormal ECG results, cardiac enlargement, decreased
LEFV, and clinical signs of heart failure). Analysis of the
twelve healthy donors showed that five of them (41.7%)
were HLA-A2+, and HLA-A*0201+.Frequency of MP-Flu* specific CD8+ T cells
Tetramer consisting of HLA-A*0201/Flu-MP* peptide was
used to evaluate the frequency of Flu-MP* specific CD8+ T
cells in the thirteen HLA-A*0201+ chagasic patients and
five HLA-A*0201+ healthy donors. Flu-MP* peptide spe-
cific cells were found in all chagasic patients, showing a
range of frequency of 0.12% to 0.36% (mean 0.21%, SD=
0.07). Likewise, in the group of healthy donors all indivi-
duals had Flu-MP* peptide specific cells with a frequency
range of 0.12% to 0.29% (mean 0.17%, SD=0.07). There
was no difference when all the groups of patients were
compared based on their clinical status (indeterminate and
cardiac chronic patients) or when chagasic patients were
compared with healthy donors (P >0.05) (Figure 1).Phenotypic characterization of Flu-MP*
specific-CD8+ T cells
Several studies showed the importance of memory CD8+
T cells in controlling viral infections in mice and human
models [28]. Consequently, the phenotype of the Flu-MP*mined by tetramer staining. (A) Representative flow cytometry dot
+ chagasic patients (white bars) and HLA-A*0201+ healthy donors
hy donors and chagasic patients P= 0.21.
Figure 2 Expression of CCR7 and CD62L in Flu-MP* peptide-specific CD8+ T cells. (A) Phenotypic characterization by flow cytometry in one
representative chagasic patient. (B) Significant differences were observed between central memory (double positive cells) T cells (TCM) and
effector memory (double negative cells) T cells (TEM) (P< 0.008) from chagasic patients (white bars) or healthy donors (grey bars). No differences
were found when the frequencies of TCM and TEM CD8
+ T cells were compared between chagasic patients and healthy donors.
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and healthy donors was determined by analyzing the ex-
pression of CCR7, CD62L, CD27 and CD28. It was found
that the Flu-MP* peptide-specific CD8+ T cells were pre-
dominately TEM (CCR7- CD62L-) in both indeterminate
and cardiac chronic chagasic patients without statistically
differences (P= 0.206). Moreover, no differences were
found when the expression in chagasic patients and
healthy donors were compared (P= 0.055). However, sig-
nificant differences were observed when the percentages
of Flu-MP* peptide specific TCM and TEM cells from cha-
gasic patients or healthy donors (P= 0.0001, and P=0.008,
respectively) were compared (Figure 2). As the CD8+ T
cell differentiation degree, based on CD28, and CD27 ex-
pression, well correlates with their functional capacity
[29], the Flu-specific CD8+ T cell stage of differentiation
was compared among donors. It was found that Flu-MP*
peptide-specific CD8+ T cells are equally distributed in the
early and intermediate/late differentiation stages without
showing any enrichment of a specific population. ThereFigure 3 Expression of CD27 and CD28 in Flu-MP* peptide-specific CD
in one representative chagasic patient. (B) There were no differences betw
intermediate/late differentiation stage (CD27+ CD28-, CD27- CD28-) in CD8
chagasic patients (white bars) and healthy donors (grey bars) when compa
differentiation stage (P= 0.430).were no statistically significant differences between chaga-
sic patients and healthy donors (Figure 3).
Functional characterization of Flu-MP*
specific-CD8+ T cells
To assess the functional characteristics of Flu-MP* spe-
cific CD8+ T cells, the IL-2 and IFNγ cytokine production
and cytotoxic capacity, measured by the perforin secretion
and CD107a/b surface expression, were evaluated in
PBMC from ten chagasic patients and 5 healthy donors.
For perforin analysis, it was observed that Flu-MP* pep-
tide specific CD8+ T cells from T. cruzi-infected volun-
teers had similar percentage of expression, ranging from
17.56% to 77.78% (mean 41.4%, SD=20.60%), than that
from the healthy group of donors which ranged from
30.3% to 61.5% (mean 50.62%, SD=12.05%). The surface
expression of CD107a/b was detected in Flu-MP* peptide
specific CD8+ T cells from both chagasic patients and
healthy donors, with percentages ranging from 0.52 to
5.71% (mean 2.50%, SD=2.05%) and 0.47% to 24.2%8+ T cells. (A) Flow cytometry dot plot of CD27 and CD28 expression
een the early differentiation phenotype (CD27+ CD28+) and the
+ T cells (P> 0.151). There were no significant differences between the
ring the early phenotype (P= 0.139) with intermediate/late
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differences in percentage, mean fluorescence intensity
(MFI) or integrated mean fluorescence intensity (iMFI) in
CD107a/b between chagasic patients and healthy donors
were observed (Figure 4A, 4B). IL-2 was detected in eight
out of ten infected patients with a range from 0.21% to
7.37% (mean 1.87%, SD=2.6%) and in all studied healthy
donors with a range from 0.56% to 1.57% (mean 1.09%,
SD= 0.42%). IFNγ production was detected in Flu-MP*
specific CD8+ T cells with a range from 0.51% to 3.42%
(mean 1.61%, SD=1.13%) in nine out of ten chagasic
patients and in all healthy donors with a frequency range
of 1.33% to 3.07% (mean 2.06%, SD= 0.74%). Conse-
quently, no differences in cytokines production wereFigure 4 Functional characterization of CD8+ T cells specific for Flu-M
fluorescence intensity (MFI) and integrated mean fluorescence intensity (iM
CD8+ T cells specific for Flu-MP* peptide in chagasic patients (white bars) a
expression of each studied molecule from one HLA-A*0201+ chagasic patieobserved in terms of percentage, MFI or iMFI when both
groups were compared (Figure 4C, 4D).
Discussion
Chagas disease is a persistent parasitic infection that does
not induce sterilizing immunity. The generation of mem-
ory T cell response depends on the environmental condi-
tions at the initial antigenic priming [30]. Indeed, the T
cell responses may be influenced by previous antigen
encounters, a phenomenon known as “original antigenc
sin” [31]. Thus, the goal of this study was to determine
whether chagasic patients are able to respond against a
non-T. cruzi microbial antigen such as the matrix peptide
derived from influenza virus. Exposure to influenza virusP* peptide determinated by flow cytometry. Frequency, mean
FI) of the perforin (A), CD107a/b (B), IFNγ (C) and IL-2 (D) expression in
nd healthy donors (grey bars). A representative dot plot of the
nt is shown on the right side.
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serotype-dependent sterilizing immunity.
At first, frequency of Flu-MP* peptide-specific CD8+ T
cells from chronic chagasic patients and healthy donors
was studied. Noticeably, no differences were found be-
tween these two groups. Moreover, the average frequency
values were similar to those previously reported for the in-
fluenza-M158–66 (GILGFVFTL) specific CD8
+ T cells
(0.28% to 0.73%) from healthy donors [32]. A similar Flu-
MP tetramer positive cell frequency (0.11% to 0.56%) was
reported in six HLA-A*0201+ healthy donors [33]. Like-
wise, in a previous study we reported the existence of Flu-
MP*-specific CD8+ T cells with frequencies up to 0.36% in
16 out of 19 HLA-A2+ chagasic patients and frequencies
up to 0.25% in 10 out of 12 healthy donors without statis-
tically significant difference when non-chagasic and T.
cruzi infected individuals were compared (P> 0.05) [34].
Memory T cells consist in central (TCM) and effector
(TEM) memory cells [28,30,35]. While human TCM express
CCR7 and CD62L, molecules involved in cellular homing
to lymphoid tissue, human TEM have lost the expression
of CCR7 and CD62L and preferentially migrate to non-
immune tissues [28]. In this study, Flu-MP* peptide-
specific CD8+ T cells were predominately TEM cells, in
both healthy donors and chagasic patients. Results that
are in agreement with reports of Hoji et al., showing that
Flu-specific T cells from healthy donors had a lower pro-
portion of CCR7 expression on Flu-specific T cells and a
moderate expression of CD62L with a phenotype that cor-
responds to effector memory CD8+ T cells [33]. Expres-
sion of CD27 and CD28 are useful in distinguishing CD8+
T cell differentiation stages: early (CD27+ CD28+), inter-
mediate (CD27+ CD28-) and late differentiation (CD27-
CD28-) [28]. In our study, in the influenza-specific CD8+
T cells there was not a predominant population based on
CD27 and CD28 expression. During chronic viral infec-
tion, and depending on the infecting virus, there is a cer-
tain predominance of a cell stage of differentiation [29].
Nonetheless, we could not find any report in the literature
showing the expression of these markers in influenza-
specific CD8+ T cells to be compared with our results.
CD8+ TEM cells have cytotoxic granules and produce
cytokines within hours after antigenic stimulation. MP-
Flu* peptide-specific CD8+ T cells expressed surface
CD107a/b and were able to secrete IL-2, IFNγ and storage
perforin. Interestingly, in both infected patients and
healthy donors, the expression of IL-2, IFNγ and perforin
by Flu-MP* peptide-specific CD8+ T cells was similar in
magnitude (percentage of expressing cells), quality (MFI)
or both (iMFI), indicating that these populations are
equally functional upon Flu-MP* peptide recognition.
In agreement with results presented here, a study of
congenital Chagas disease performed in newborns con-
genitally infected with T. cruzi, showed that the infectiondid not interfere with responses to Bacillus Calmette
Guerin (BCG), hepatitis B, diphtheria, and tetanus vac-
cines during the neonatal period [36].
Conclusion
Our results support the hypothesis that there is no CD8+
T cell nonspecific immune-suppression during chronic
Chagas disease infection. Nonetheless, other viral antigens
must be studied in order to confirm our findings.
Methods
Subjects
All individuals enrolled in the study were volunteers who
signed the informed consent form and were clinically eval-
uated at Fundación Abood Clínica Shaio and the Instituto
Nacional de Salud (Bogotá, Colombia). Fifty Chagas dis-
ease patients with positive results in both immunofluores-
cence assays (IFI) and enzyme-linked immunosorbent
assays (ELISA) were evaluated. Patients were classified
according to the classification of the Incorporating Ameri-
can College of Cardiology and the American Heart Asso-
ciation Staging [37,38], as follows: twenty-one chronic
chagasic patients at indeterminate phase of the disease
with normal ECG and no major findings arising during
clinical examination (group A), and twenty nine cardiac
chronic chagasic patients with abnormal ECG, having dif-
ferent disease severity levels (groups B, C and D). The
group of healthy donors consisted of twelve T. cruzi sero-
negative individuals residing in non-endemic areas with
normal ECG and no major clinical findings during clinical
examination. Approximately a total of 20 mL of blood was
obtained from all individuals by venipuncture in hepari-
nized tubes to separate peripheral blood mononuclear
cells (PBMCs), EDTA tubes for DNA extraction and tubes
without anticoagulant for serological tests (Vacutainer;
Beckton-Dickinson, San José, CA, USA). This study was
approved by the Research and Ethics Committees from
the Facultad de Ciencias, Pontificia Universidad Javeriana
and Fundación Abood Clínica Shaio.
Flu-MP* modified peptide
An HLA-A*0201 restricted peptide derived from the influ-
enza virus matrix protein58-66 with a modification in the
seventh position was used (GILGFVTTL) and referred as
Flu-MP* [19,34,39]. Peptide was synthesized using 9-
fluorenylmethiloxycarbonyl (Fmoc) chemistry with a 0.64
substituted rink amide resin and Fmoc amino acids [40].
The peptides were cleaved by treatment with trifluoroace-
tic acid (TFA)/triisopropylsilan (TIS)/H2O (95/5/5) for
1 h, then precipitated with cold diethyl ether and purified
by reverse phase high performance liquid chromatography
(HPLC). The molar mass of the peptides was determined
by MALDI-TOF mass spectrometry. The lyophilized
Lasso et al. BMC Infectious Diseases 2012, 12:198 Page 6 of 8
http://www.biomedcentral.com/1471-2334/12/198peptide was reconstituted in dimethyl sulfoxide (DMSO)
and stored at −20°C.
HLA-A2 typing by flow cytometry
Individual HLA-A2 typing was performed by incubating
50 μL of peripheral blood with HLA-A2-specific antibody
BB7⋅2-FITC (Becton Dickinson, Mountain View, Califor-
nia, USA) for 20 min at 4°C, followed by additional
15 min incubation. After adding red blood cells lysis buf-
fer and 1X PBS washing [41], data were acquired and ana-
lyzed using a FACSCanto II flow cytometer and analyzed
using FACSDiva (BD Biosciences) software.
HLA-A*0201 subtyping by PCR
A total of 50–150 ng genomic DNA was extracted from
peripheral blood using a GFX genomic blood DNA puri-
fication kit (Amersham Biosciences, Piscataway, NJ,
USA), and amplified using the 296 (5′-GTGGATAGAG-
CAGGAGGCT-3′), and 302 (5′-CCAAGAGCGCAGG-
TCCTCT-3′) primers. The PCR reaction was carried out
according to Lasso et al. 2010 in a Stomacher 3500
Thermal Cycler, PTC 100 (MJ Research, Watertown,
MA, USA) [34]. The expected 489 bp amplified product
was separated on ethidium bromide stained 1.5% agarose
gels [42].
T cell frequency determination
HLA-A2 PE-labeled tetramer loaded with the Flu-MP*
peptide, was synthesized by the National Institute of
Health (NIH) Tetramer Facility (Atlanta, USA). Peripheral
blood mononuclear cells (PBMCs) of all individuals were
prepared using Ficoll-Hypaque density gradient (Sigma,
St. Louis, MO), adjusted to 1 x 106 cells per tube and
stained with tetramer at 0,5 μg/mL, anti-CD3-PerCP and
anti-CD8-FITC (BD Biosciences, San José, CA, USA) for
20 min in the dark at room temperature [34]. After wash-
ing with staining buffer (1% fetal bovine serum in PBS
1X), cells were resuspended with 500 μL of PBS 1X. Data
were acquired in a FACSCanto II flow cytometer and ana-
lyzed using FACSDiva software (BD, Bioscience, San José,
CA, USA). Frequencies of Flu-specific CD8+ T cells are
the result of the frequency obtained minus the back-
ground of unlabeled cells with the tetramer.
T cell phenotyping and function
PBMCs were adjusted to 2 x 106 cells per tube and la-
beled with tetramers at 0.5 μg/mL, anti-CD3-PerCP, anti-
CD8-APC-Cy7, anti-CCR7-PECy7, anti-CD62L-APC for
20 min in the dark at room temperature (all antibodies
were purchased from BD Biosciences and BD Pharmin-
gen, San Diego, CA, USA). After washing with 2 mL
staining buffer (1% fetal bovine serum in PBS 1X), cells
were fixed with 0.5% formaldehyde in PBS 1X. To deter-
mine intracellular perforin expression, after surfaceantigens staining, CD8+ T cells were permeabilized with
Cytofix/Cytoperm (BD Pharmingen), washed twice with
Perm/WashTM (BD Pharmingen) and stained with anti-
perforin-FITC or mouse IgG2b κ isotype control for
30 min at 4°C. Intracellular cytokines were detected in
PBMCs stimulated with Flu-MP* peptide in the presence of
CD28 (1 μg/mL), and CD49d (1 μg/mL) for 12 h at 37°C.
The last 9 h of culture were performed in the presence of
brefeldin A (10 μg/mL) (BD Pharmingen). Then, cells were
permeabilized and stained with anti-IFNγ-PECy7 and anti-
IL-2-APC for 30 min at 4°C. To evaluate the cytotoxic ac-
tivity, anti-CD107a and anti-CD107b-FITC were added to
the PBMCs prior to stimulation. In each experiment, non-
stimulated cells were used as negative control and Staphylo-
coccal enterotoxin B (3.7 μg/mL) as positive control. Data
were acquired in a FACSCanto II flow cytometer and ana-
lyzed using FACSDiva (BD Biosciences) software. Results
were expressed as percentage, mean fluorescence intensity
(MFI) and integrated mean fluorescence intensity (iMFI)
obtained multiplying the frequency by the MFI. The latter
was obtained multiplying the frequency by the MFI of tetra-
mer positive CD8+ T cells [43].
Statistical methods
Differences among groups were assessed by Mann Whit-
ney test. GraphPad InStat 3.0 statistics software was used
for analyses. P < 0.05 was considered statistically significant.
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